Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov;19(11):5284-5288.
doi: 10.1002/alz.13093. Epub 2023 Apr 18.

Meeting report of the annual workshop on Principles and Techniques for Improving Preclinical to Clinical Translation in Alzheimer's Disease research

Michael Sasner  1 , Paul R Territo  2 , Stacey J Sukoff Rizzo  3
Affiliations

Meeting report of the annual workshop on Principles and Techniques for Improving Preclinical to Clinical Translation in Alzheimer's Disease research

Michael Sasner et al. Alzheimers Dement. 2023 Nov.

Abstract

Introduction: The second annual 5-day workshop on Principles and Techniques for Improving Preclinical to Clinical Translation in Alzheimer's Disease Research was held October 7-11, 2019, at The Jackson Laboratory in Bar Harbor, Maine, USA, and included didactic lectures and hands-on training. Participants represented a broad range of research across the Alzheimer's disease (AD) field, and varied in career stages from trainees and early stage investigators to established faculty, with attendance from the United States, Europe, and Asia.

Methods: In line with the National Institutes of Health (NIH) initiative on rigor and reproducibility, the workshop aimed to address training gaps in preclinical drug screening by providing participants with the skills and knowledge required to perform pharmacokinetic, pharmacodynamics, and preclinical efficacy experiments.

Results: This innovative and comprehensive workshop provided training in fundamental skill sets for executing in vivo preclinical translational studies.

Discussion: The success of this workship is expected to translate into practical skills that will enable the goals of improving preclinical to clinical translational studies for AD.

Highlights: Nearly all preclinical studies in animal models have failed to translate to successful efficacious medicines for Alzheimer's disease (AD) patients. While a wide variety of potential causes of these failures have been proposed,deficiencies in knowledge and best practices for translational research are not being sufficiently addressed by common training practices. Here we present proceedings from an annual NIA-sponsored workshop focused specifically on preclinical testing paradigms for AD translational research in animal models aimed at enabling improved preclinical to clinical translation for AD.

Keywords: Alzheimer's disease; best practices; mouse models; preclinical translation; rigor and reproducibility; training.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
The annual workshop on Principles and Techniques for Improving Preclinical Translation of Alzheimer’s Disease Research provides participants with the skills and knowledge required to perform pharmacokinetic, pharmacodynamics, and preclinical efficacy experiments by leveraging the rigorous best practices and approaches of the MODEL-AD Preclinical Testing Core. This innovative and comprehensive workshop provides training in fundamental skill sets for executing in vivo preclinical translational studies with the goal of improving preclinical to clinical translational studies for AD.
See this image and copyright information in PMC

References

    1. Sukoff Rizzo SJ, Masters A, Onos KD, Quinney S, Sasner M, Oblak A, Lamb BT, Territo PR; MODEL-AD consortium. Improving preclinical to clinical translation in Alzheimer's disease research. Alzheimers Dement (N Y). 2020. Jun 14;6(1):e12038. doi: 10.1002/trc2.12038. - DOI - PMC - PubMed
    1. Shineman DW, Basi GS, Bizon JL, Colton CA, Greenberg BD, Hollister BA, Lincecum J, Leblanc GG, Lee LB, Luo F, Morgan D, Morse I, Refolo LM, Riddell DR, Scearce-Levie K, Sweeney P, Yrjänheikki J, Fillit HM. Accelerating drug discovery for Alzheimer's disease: best practices for preclinical animal studies. Alzheimers Res Ther. 2011. Sep 28;3(5):28. doi: 10.1186/alzrt90. - DOI - PMC - PubMed
    1. Oblak AL, Forner S, Territo PR, Sasner M, Carter GW, Howell GR, Sukoff-Rizzo SJ, Logsdon BA, Mangravite LM, Mortazavi A, Baglietto-Vargas D, Green KN, MacGregor GR, Wood MA, Tenner AJ, LaFerla FM, Lamb BT; and The MODEL-AD; Consortium. Model organism development and evaluation for late-onset Alzheimer's disease: MODEL-AD. Alzheimers Dement (N Y). 2020. Nov 23;6(1):e12110. doi: 10.1002/trc2.12110. - DOI - PMC - PubMed
    1. Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, Browne WJ, Clark A, Cuthill IC, Dirnagl U, Emerson M, Garner P, Holgate ST, Howells DW, Karp NA, Lazic SE, Lidster K, MacCallum CJ, Macleod M, Pearl EJ, Petersen OH, Rawle F, Reynolds P, Rooney K, Sena ES, Silberberg SD, Steckler T, Würbel H. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. PLoS Biol. 2020. Jul 14;18(7):e3000410. doi: 10.1371/journal.pbio.3000410. - DOI - PMC - PubMed
    1. Seyhan AA Lost in translation: the valley of death across preclinical and clinical divide – identification of problems and overcoming obstacles. transl med commun 4, 18 (2019). 10.1186/s41231-019-0050-7 - DOI

Publication types